Celldex Therapeutics (CLDX) Accumulated Depreciation (2011 - 2025)

Celldex Therapeutics' Accumulated Depreciation history runs 15 years deep, the most recent figure standing at $23.9 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 1.88% year-over-year to $23.9 million; the TTM figure through Dec 2025 stood at $23.9 million (up 1.88% YoY), while the FY2025 annual figure was $23.9 million, up 1.88% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $23.9 million, up from $23.5 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $23.9 million in Q4 2025, with the low at $21.1 million in Q4 2021.
• The 5-year median for Accumulated Depreciation is $22.4 million (2023), against an average of $22.5 million.
• The sharpest annual moves came in 2021 and 2024: Accumulated Depreciation dropped 0.52% in 2021, then rose 4.82% in 2024.
• Celldex Therapeutics' Accumulated Depreciation stood at $21.1 million in 2021, then climbed by 2.37% to $21.6 million in 2022, then climbed by 3.51% to $22.4 million in 2023, then advanced by 4.82% to $23.5 million in 2024, then grew by 1.88% to $23.9 million in 2025.
• Business Quant data shows CLDX's Accumulated Depreciation at $23.9 million in Q4 2025, $23.5 million in Q4 2024, and $22.4 million in Q4 2023.